Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study

Zhang, Li; Hou, Xue; Lu, Shun; Rao, Hui‐Lan; Hou, Jingyuan; Luo, Rongzhen; Huang, He; Zhao, Hongyun; Hong, Jian; Chen, Zhiwei; Liao, Meilin; Wang, Xin

doi:10.1016/j.lungcan.2009.03.017

Cited by 44 publications

(44 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic value of BSP in BM of NSCLC patients was documented in several studies [5,6,10]. In the present study,wefoundthattheserumBSPlevelwasassociatedwith BM-freesurvivalofsubjectswithNSCLC.HigherserumBSP levelswereapredictorforshorterBM-freesurvival,suggestingthatserumBSPmaybeusedasaprognosticbiomarkerin NSCLC.…”

Section: Serum Levels Of Bsp Cea and Cyfra 21-1supporting

confidence: 78%

“…The difference between healthy controls and non-BM NSCLC patients was also significant(p< 0.05).Spearmananalysesshowednocorrelations between ages and serum BSP levels in each group (all p>0.05).ThelevelsofserumBSPdidnotdiffersignificantly with sex distribution or tumor histology. However, when serumBSPlevelswerecomparedaccordingtothepathological stage, advanced NSCLC (stages III/IV) subjects had a markedly higher mean serum BSP level than those with [5]investigatedtheexpressionofBSPin180surgically resectedNSCLCpatientsandfoundthatBSPproteinexpression was strongly associated with BM and could be used to identifyhigh-riskpatients.Inotherinvivoexperiments [6][7][8], primary tumors were investigated by immunohistochemistry for 10 markers involved in bone resorption or development of metastases. It was suggested that BSP protein expression in primary resected NSCLC was strongly associated with BM progression and could be useful in identifying patients at high risk of developing BM.…”

Section: Serum Levels Of Bsp Cea and Cyfra 21-1mentioning

confidence: 99%

See 1 more Smart Citation

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Zhi²,

Li³

2011

Onkologie

View full text Add to dashboard Cite

Background: The purpose of this study was to evaluate the diagnostic and prognostic significance of serum bone sialoprotein (BSP) in patients with bone metastasis (BM) from non-small cell lung cancer (NSCLC). Patients and Methods: A total of 146 patients diagnosed with NSCLC and 110 healthy controls were enrolled in this study. The clinical characteristics including clinical stage, pathological type, smoking status, and ECOG performance status were obtained. The mean serum BSP was detected by sandwich ELISA. Results: The mean serum BSP level in individuals with BM was significantly higher than those in non-BM NSCLC and controls (p < 0.001). Receiver operating characteristics (ROC) analysis showed that BSP discriminated patients with BM from non-BM NSCLC patients at the cutoff value of 33.56 ng/ml. Sensitivity and specificity were 77.8 and 81.1%, respectively. Kaplan-Meier analysis showed that subjects with higher BSP levels had a shorter BM-free period than those with lower BSP levels. Cox regression analysis revealed that the BSP level was a predictor for prognosis of BM from NSCLC. Conclusion: Serum BSP is a useful biomarker for the diagnosis of BM from NSCLC, and can be regarded as an independent factor for predicting the prognosis of BM from NSCLC.

show abstract

Section: Serum Levels Of Bsp Cea and Cyfra 21-1supporting

confidence: 78%

Section: Serum Levels Of Bsp Cea and Cyfra 21-1mentioning

confidence: 99%

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Zhi²,

Li³

2011

Onkologie

View full text Add to dashboard Cite

show abstract

“…A further 2 studies were excluded [one focused on the association between OPN and bone metastases (17), whereas the other provided limited data on HR and 95% CI (18) and the authors were unavailable for more detailed information]. In addition, after performing an in-depth check of the literature, we found that the same cohort was enrolled in two reports (19,20) and only considered the study by Donati et al (19), which had a larger sample size and included more detailed information.…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Zou

Wang

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Osteopontin (OPN) plays an important role in the progression and metastasis of cancer. However, the role of OPN as a prognostic factor in non-small-cell lung cancer (NSCLC) remains controversial. The aim of this study was to investigate the association between OPN expression and prognosis in patients with NSCLC using a meta-analysis. Based on PubMed, Ovid Medline, Embase, ISI, ScienceDirect and SpringerLink databases, related articles published prior to January, 2013 were collected. A meta-analysis was conducted to investigate the association of OPN expression with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) was used to assess the strength of this association. A total of 6 studies, including 776 patients, were found to be eligible for the meta-analysis. No heterogeneity was observed in OS or PFS, whereas low OPN expression was found to be correlated with better OS (HR=0.57, 95% CI: 0.46-0.70) and PFS (HR=0.62, 95% CI: 0.49-0.77). This meta-analysis demonstrated an association of OPN with poor prognosis in NSCLC patients. However, prospective studies are required to confirm these findings.

show abstract

“…Furthermore, bone sialoprotein (BSP) and osteopontin (OPN), two secreted glycoproteins regulated by TGF-β, play important roles in bone turnover and were found to be highly expressed in malignant prostate and breast cancer tissue and correlated with tumor grade. In these patients, serum and mRNA levels of BSP and OPN were identified to be prognostic indicators for bone metastases [100][101][102][103].…”

Section: Tgf-β In Bone Metastasismentioning

confidence: 99%

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases

Buijs

Stayrook

Guise

2011

Cancer Microenvironment

View full text Add to dashboard Cite

Breast cancer is the most prevalent cancer among females worldwide. It has long been known that cancers preferentially metastasize to particular organs, and bone metastases occur in ∼70% of patients with advanced breast cancer. Breast cancer bone metastases are predominantly osteolytic and accompanied by bone destruction, bone fractures, pain, and hypercalcemia, causing severe morbidity and hospitalization. In the bone matrix, transforming growth factor-β (TGF-β) is one of the most abundant growth factors, which is released in active form upon tumor-induced osteoclastic bone resorption. TGF-β, in turn, stimulates bone metastatic cells to secrete factors that further drive osteolytic destruction of the bone adjacent to the tumor, categorizing TGF-β as a crucial factor responsible for driving the feed-forward vicious cycle of cancer growth in bone. Moreover, TGF-β activates epithelial-to-mesenchymal transition, increases tumor cell invasiveness and angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between breast cancer and bone offers a promising target for therapeutic intervention to decrease skeletal metastasis. This review will describe the role of TGF-β in breast cancer and bone metastasis, and pre-clinical and clinical data will be evaluated for the potential use of TGF-β inhibitors in clinical practice to treat breast cancer bone metastases.

show abstract

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study

Cited by 44 publications

References 39 publications

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases

Contact Info

Product

Resources

About